Report Detail
(Post-pandemic Era)-Global Radiopharmaceuticals in Nuclear Medicine Market Assessment, With Major Companies Analysis, Regional Analysis, Breakdown Data by Application/Type
- RnM4152108 |
- 22 August, 2020 |
- Global |
- 115 Pages |
- XYZResearch |
- Other
Summary
This study analysis was given on a worldwide scale, for instance, present and historical Radiopharmaceuticals in Nuclear Medicine growth analysis, competitive analysis, and also the growth prospects of the major regions. The report gives an exhaustive investigation of this market at country & regional levels, and provides an analysis of the industry trends in each of the sub-segments, from production, revenue and consumption. A quantitative and qualitative analysis of the main players in related regions is introduced, from the perspective of Radiopharmaceuticals in Nuclear Medicine production, Radiopharmaceuticals in Nuclear Medicine revenue, Radiopharmaceuticals in Nuclear Medicine consumption and Radiopharmaceuticals in Nuclear Medicine price.
According to the current situation, the official counts of cases and deaths from COVID-19 have passed 4,000,000 and 280,000 at the time of this report. Many government announced a plan on reopening the national economy, but many countries are still at the stage of rising. XYZResearch published a report for global Radiopharmaceuticals in Nuclear Medicine market in this environment.
In terms of revenue, this research report indicated that the global Radiopharmaceuticals in Nuclear Medicine market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Radiopharmaceuticals in Nuclear Medicine industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the production and revenue data in each of the sub-segments.
The Bracco Imaging S.P.A. aims at producing XX Radiopharmaceuticals in Nuclear Medicine in 2020, with XX % production to take place in global market, ????Cambridge Isotope Laboratories, Inc. accounts for a volume share of XX %.
At the upcoming analysis, this report discusses industrial policy, economic environment, in addition to the COVID-19 impact and cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Radiopharmaceuticals in Nuclear Medicine Market by XYZResearch Include
NorthAmerica
Asia
Europe
Middle East & Africa
South America
Competitive Analysis; Who are the Major Players in Radiopharmaceuticals in Nuclear Medicine Market?
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
Major Type of Radiopharmaceuticals in Nuclear Medicine Covered in XYZResearch report:
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
Application Segments Covered in XYZResearch Market
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Radiopharmaceuticals in Nuclear Medicine Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
- 1.1 Product Details and Introduction
- 1.1.1 Diagnostic Radiopharmaceuticals -Product Introduction and Major Manufacturers
- 1.1.2 Therapy Radiopharmaceuticals -Product Introduction and Major Manufacturers
- 1.1.3 Enriched Stable Isotopes -Product Introduction and Major Manufacturers
- 1.2 Market Snapshot
- 1.2.1 Major Companies Overview
- 1.2.2 Market Concentration
- 1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Regional Market
- 2.1 Regional Market Share in Terms of Production (2019-2026)
- 2.2 Regional Market Share in Terms of Revenue (2019-2026)
- 2.3 Regional Market Share in Terms of Consumption (2019-2026)
3 Global Radiopharmaceuticals in Nuclear Medicine Market Assessment by Type
- 3.1 Global Radiopharmaceuticals in Nuclear Medicine Production by Type (2015-2026)
- 3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2015-2026)
- 3.3 North America Radiopharmaceuticals in Nuclear Medicine Production and Revenue by Type (2015-2026)
- 3.4 Asia Radiopharmaceuticals in Nuclear Medicine Production and Revenue by Type (2015-2026)
- 3.5 Europe Radiopharmaceuticals in Nuclear Medicine Production and Revenue by Type (2015-2026)
- 3.6 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Production and Revenue by Type (2015-2026)
- 3.7 South America Radiopharmaceuticals in Nuclear Medicine Production and Revenue by Type (2015-2026)
4 Global Radiopharmaceuticals in Nuclear Medicine Market Assessment by Application
- 4.1 Historical & Forecast Global Radiopharmaceuticals in Nuclear Medicine Consumption, Different Application Field (2015-2026)
- 4.2 Historical & Forecast North America Radiopharmaceuticals in Nuclear Medicine Consumption, Different Application Field (2015-2026)
- 4.3 Historical & Forecast Asia Radiopharmaceuticals in Nuclear Medicine Consumption, Different Application Field (2015-2026)
- 4.4 Historical & Forecast Europe Radiopharmaceuticals in Nuclear Medicine Consumption, Different Application Field (2015-2026)
- 4.5 Historical & Forecast Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Consumption, Different Application Field (2015-2026)
- 4.6 Historical & Forecast South America Radiopharmaceuticals in Nuclear Medicine Consumption, Different Application Field (2015-2026)
5 North America
- 5.1 US Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 5.2 Canada Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 5.3 Mexico Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
6 Asia
- 6.1 China Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 6.2 Japan Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 6.3 India Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 6.4 Korea Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 6.5 Southeat Asia Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
7 Europe
- 7.1 Germany Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 7.2 UK Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 7.3 France Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 7.4 Russia Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 7.5 Italy Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
8 Middle East and Africa
- 8.1 Saudi Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 8.2 UAE Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 8.3 Egypt Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 8.4 Nigeria Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 8.5 South Africa Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
9 South America
- 9.1 Brazil Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 9.2 Argentina Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
- 9.3 Colombia Radiopharmaceuticals in Nuclear Medicine Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
10 Global Radiopharmaceuticals in Nuclear Medicine Average Price Trend
- 10.1 Market Price for Each Type of Radiopharmaceuticals in Nuclear Medicine in North America (2015-2026)
- 10.2 Market Price for Each Type of Radiopharmaceuticals in Nuclear Medicine in Asia (2015-2026)
- 10.3 Market Price for Each Type of Radiopharmaceuticals in Nuclear Medicine in Europe (2015-2026)
- 10.4 Market Price for Each Type of Radiopharmaceuticals in Nuclear Medicine in Middle East & Africa (2015-2026)
- 10.5 Market Price for Each Type of Radiopharmaceuticals in Nuclear Medicine in South America (2015-2026)
11 Value Chain (Impact of COVID-19)
- 11.1 Radiopharmaceuticals in Nuclear Medicine Value Chain Analysis
- 11.1.1 Upstream
- 11.1.2 Downstream
- 11.2 COVID-19 Impact on Radiopharmaceuticals in Nuclear Medicine Industry
- 11.2.1 Industrial Policy Issued Under the Epidemic Situation
- 11.3 Cost-Under the Epidemic Situation
- 11.3.1 Cost of Raw Material
- 11.4 Channel Analysis
- 11.4.1 Distribution Channel-Under the Epidemic Situation
- 11.4.2 Distributors
12 Radiopharmaceuticals in Nuclear Medicine Competitive Analysis
- 12.1 Bracco Imaging S.P.A.
- 12.1.1 Bracco Imaging S.P.A. Company Profiles
- 12.1.2 Bracco Imaging S.P.A. Product Introduction
- 12.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Production, Revenue (2015-2020)
- 12.1.4 SWOT Analysis
- 12.2 Cambridge Isotope Laboratories, Inc.
- 12.2.1 Cambridge Isotope Laboratories, Inc. Company Profiles
- 12.2.2 Cambridge Isotope Laboratories, Inc. Product Introduction
- 12.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Production, Revenue (2015-2020)
- 12.2.4 SWOT Analysis
- 12.3 Cardinal Health, Inc.
- 12.3.1 Cardinal Health, Inc. Company Profiles
- 12.3.2 Cardinal Health, Inc. Product Introduction
- 12.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Production, Revenue (2015-2020)
- 12.3.4 SWOT Analysis
- 12.4 Covidien, Plc
- 12.4.1 Covidien, Plc Company Profiles
- 12.4.2 Covidien, Plc Product Introduction
- 12.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Production, Revenue (2015-2020)
- 12.4.4 SWOT Analysis
- 12.5 Isotec, Inc. (Sigma-Aldrich)
- 12.5.1 Eczacibasi-Monrol Company Profiles
- 12.5.2 Eczacibasi-Monrol Product Introduction
- 12.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Production, Revenue (2015-2020)
- 12.5.4 SWOT Analysis
- 12.6 Fujifilm Holdings Corporation
- 12.6.1 Fujifilm Holdings Corporation Company Profiles
- 12.6.2 Fujifilm Holdings Corporation Product Introduction
- 12.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Production, Revenue (2015-2020)
- 12.6.4 SWOT Analysis
- 12.7 GE Healthcare (Subsidiary Of General Electric Company)
- 12.7.1 GE Healthcare (Subsidiary Of General Electric Company) Company Profiles
- 12.7.2 GE Healthcare (Subsidiary Of General Electric Company) Product Introduction
- 12.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Production, Revenue (2015-2020)
- 12.7.4 SWOT Analysis
- 12.8 IBA Group
- 12.8.1 IBA Group Company Profiles
- 12.8.2 IBA Group Product Introduction
- 12.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Production, Revenue (2015-2020)
- 12.8.4 SWOT Analysis
- 12.9 Isotec, Inc. (Sigma-Aldrich)
- 12.9.1 Isotec, Inc. (Sigma-Aldrich) Company Profiles
- 12.9.2 Isotec, Inc. (Sigma-Aldrich) Product Introduction
- 12.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Production, Revenue (2015-2020)
- 12.9.4 SWOT Analysis
- 12.10 Lantheus Medical Imaging, Inc.
- 12.10.1 Lantheus Medical Imaging, Inc. Company Profiles
- 12.10.2 Lantheus Medical Imaging, Inc. Product Introduction
- 12.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Production, Revenue (2015-2020)
- 12.10.4 SWOT Analysis
- 12.11 Nordion, Inc.
- 12.12 Ntp Radioisotopes (Pty), Ltd.
- 12.13 Siemens Healthcare (Subsidiary Of Siemens AG)
- 12.14 Taiyo Nippon Sanso Corporation
- 12.15 Urenco Limited
- 12.16 Rotem Industries, Ltd., Inc.
- 12.17 Australian Nuclear Association And Technology Organization (ANSTO)
- 12.18 Board of Radiation And Isotope Technology (BRIT)
- 12.19 Institute of Atomic Energy Polatom Radioisotope Centre
- 12.20 Institute of Isotopes Co., Ltd.
- 12.21 Institute Of Radioelement (IRE)
13 Conclusion
Summary:
Get latest Market Research Reports on Radiopharmaceuticals in Nuclear Medicine. Industry analysis & Market Report on Radiopharmaceuticals in Nuclear Medicine is a syndicated market report, published as (Post-pandemic Era)-Global Radiopharmaceuticals in Nuclear Medicine Market Assessment, With Major Companies Analysis, Regional Analysis, Breakdown Data by Application/Type. It is complete Research Study and Industry Analysis of Radiopharmaceuticals in Nuclear Medicine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
